James Zweibel

Phase II trial of vorinostat in advanced melanoma

Naomi B. Haas, Ian Quirt, Sebastién J. Hotte et al. · Investigational New Drugs · 2014 · 70 citations

Medicine, Oncology, Pharmacotherapy +13

Affinity for the insulin-like growth factor-II (IGF-II) receptor inhibits autocrine IGF-II activity in MCF-7 breast cancer cells.

Matthew J. Ellis, Brett Leav, Zhi-Zheng Yang et al. · Molecular Endocrinology · 1996 · 66 citations · Full text

Life Sciences, Endocrinology, Molecular Biology +16

Phase I Trial of Suberoylanilide Hydroxamic Acid (SAHA) + Bortezomib (Bort) in Relapsed Multiple Myeloma (MM) Patients (pts).

Ashraf Badros, S. Philip, Rubén Niesvizky et al. · Blood · 2007 · 25 citations

Medicine, Hematology, Pharmacology +14

State of the Translational Science

Arthur Zelent, Samuel Waxman, Michael Carducci et al. · Clinical Cancer Research · 2004 · 24 citations

Medicine, Molecular Biology, Oncology +17

Phase I trial of vorinostat plus bortezomib (bort) in relapsed/refractory multiple myeloma (mm) patients (pts)

A. Badros, S. Philip, R. Niesvizk et al. · Journal of Clinical Oncology · 2008 · 20 citations

Medicine, Pharmacology, Pharmacotherapy +16